Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Apr 1, 2026 · Filed Apr 3, 2026
The money chief of ResMed| sold $224K of ResMed| shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$224,310
Shares × reported transaction price
62 days after results of Jan 29, 2026, 29 days before results of Apr 30, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $222.85 on Apr 1, 2026, 9% above its 52-week low and 24% below its high, after a 14% drop over the previous 30 trading days
52-week range $204.54 (Apr 8, 2025) to $293.73 (Aug 22, 2025), 21% of the way up, from 251 adjusted closes. 30 trading days earlier: $258.91 on Feb 18, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.4% | +4.1% | -1.8% |
| 30 days | -6.8% | +11.4% | -18.2% |
| 90 days | -2.9% | +14.0% | -16.9% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.